These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 18561029)
21. Magnetic activated release of umbelliferone from lipid matrices. Yi D; Zeng P; Wiedmann TS Int J Pharm; 2010 Jul; 394(1-2):143-6. PubMed ID: 20438822 [TBL] [Abstract][Full Text] [Related]
22. Cellular level loading and heating of superparamagnetic iron oxide nanoparticles. Kalambur VS; Longmire EK; Bischof JC Langmuir; 2007 Nov; 23(24):12329-36. PubMed ID: 17960940 [TBL] [Abstract][Full Text] [Related]
23. Solid Lipid-Polymer Hybrid Nanoparticles by In Situ Conjugation for Oral Delivery of Astaxanthin. Wang T; Hu Q; Lee JY; Luo Y J Agric Food Chem; 2018 Sep; 66(36):9473-9480. PubMed ID: 30130387 [TBL] [Abstract][Full Text] [Related]
24. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Das S; Ng WK; Tan RB Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358 [TBL] [Abstract][Full Text] [Related]
25. Metal carbonyls supported on iron oxide nanoparticles to trigger the CO-gasotransmitter release by magnetic heating. Kunz PC; Meyer H; Barthel J; Sollazzo S; Schmidt AM; Janiak C Chem Commun (Camb); 2013 May; 49(43):4896-8. PubMed ID: 23609342 [TBL] [Abstract][Full Text] [Related]
26. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration. Song A; Zhang X; Li Y; Mao X; Han F Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734 [TBL] [Abstract][Full Text] [Related]
27. Drug distribution in nanostructured lipid particles. Saeidpour S; Lohan SB; Solik A; Paul V; Bodmeier R; Zoubari G; Unbehauen M; Haag R; Bittl R; Meinke MC; Teutloff C Eur J Pharm Biopharm; 2017 Jan; 110():19-23. PubMed ID: 27789357 [TBL] [Abstract][Full Text] [Related]
28. Iron oxide-doped niosomes as drug carriers for magnetically targeted drug delivery. Juneja R; Roy I Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):7-9. PubMed ID: 29593388 [TBL] [Abstract][Full Text] [Related]
30. A Smart Magnetically Active Nanovehicle for on-Demand Targeted Drug Delivery: Where van der Waals Force Balances the Magnetic Interaction. Panja S; Maji S; Maiti TK; Chattopadhyay S ACS Appl Mater Interfaces; 2015 Nov; 7(43):24229-41. PubMed ID: 26458134 [TBL] [Abstract][Full Text] [Related]
31. Magnetic/NIR-thermally responsive hybrid nanogels for optical temperature sensing, tumor cell imaging and triggered drug release. Wang H; Yi J; Mukherjee S; Banerjee P; Zhou S Nanoscale; 2014 Nov; 6(21):13001-11. PubMed ID: 25243783 [TBL] [Abstract][Full Text] [Related]
32. Magnetic multilamellar liposomes produced by in situ synthesis of iron oxide nanoparticles: "magnetonions". Faure C; Meyre ME; Trépout S; Lambert O; Lebraud E J Phys Chem B; 2009 Jun; 113(25):8552-9. PubMed ID: 19534563 [TBL] [Abstract][Full Text] [Related]
33. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. Vivek K; Reddy H; Murthy RS AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544 [TBL] [Abstract][Full Text] [Related]
34. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933 [TBL] [Abstract][Full Text] [Related]
35. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Kumar A; Sahoo B; Montpetit A; Behera S; Lockey RF; Mohapatra SS Nanomedicine; 2007 Jun; 3(2):132-7. PubMed ID: 17572355 [TBL] [Abstract][Full Text] [Related]
36. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Ling D; Lee N; Hyeon T Acc Chem Res; 2015 May; 48(5):1276-85. PubMed ID: 25922976 [TBL] [Abstract][Full Text] [Related]
37. Novel magnetic iron oxide nanoparticles coated with poly(ethylene imine)-g-poly(ethylene glycol) for potential biomedical application: synthesis, stability, cytotoxicity and MR imaging. Schweiger C; Pietzonka C; Heverhagen J; Kissel T Int J Pharm; 2011 Apr; 408(1-2):130-7. PubMed ID: 21315813 [TBL] [Abstract][Full Text] [Related]
38. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles. Das S; Ng WK; Tan RB Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790 [TBL] [Abstract][Full Text] [Related]
39. Stability of lipid excipients in solid lipid nanoparticles. Radomska-Soukharev A Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589 [TBL] [Abstract][Full Text] [Related]
40. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Ranpise NS; Korabu SS; Ghodake VN Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]